Alzheimer’s disease (AD) is a public health crisis. Currently, no effective strategies to prevent or slow AD exists. This is largely due to lack of biological definition of AD as well as lack of complete understanding of the mechanisms that contribute to AD pathophysiology. This presentation will highlight how biofluids-based biomarkers have great potential to address these critical issues and to enable precision medicine for AD prevention and treatment.